Navigation Links
Mutant Gene That Ups Risk for Ovarian Cancer May Aid Survival
Date:10/11/2011

o 44 percent of women with BRCA1 mutation and 25 percent of women without either mutation.

The three-year progression-free survival rate, or the time during which the tumor did not grow, was 44 percent for BRCA2 women, 22 percent for BRCA1 women and 16 percent for women with neither mutation.

Women with BRCA2 also responded better to platinum-based chemotherapy, the standard treatment for ovarian cancer.

All women with the BRCA2 mutation saw their tumor shrink in response to chemo, compared to 80 percent for women with BRCA1 and 82 percent of women with the typical form of the gene.

After treatment ended, women with BRCA2 went an average of 18 months without the tumor re-growing, compared to 12.5 months for women with BRCA1 and 11.7 months for women without either mutation, the investigators found.

To determine why women with BRCA2 respond better to chemotherapy, researchers conducted whole-exome sequencing using blood and tumor tissue samples. The exome is the portion of the genome that contains genes that code for proteins.

The BRCA gene is involved with repairing DNA errors. The BRCA mutations are believed to make women more susceptible to certain cancers because their ability to fix DNA damage is impaired, Yang said.

Platinum-based chemotherapy also causes a large amount of DNA damage.

The exome sequencing revealed that women with BRCA2 had more DNA mutations that had occurred throughout their lifetimes (as opposed to being inherited at birth) than women with BRCA1.

In women with BRCA2, the ability to repair DNA damage is impaired not just in healthy cells, but in the cancerous tissues as well.

In women with BRCA2, because the tumor cells are not able to repair themselves against the assault of the platinum, that means the tumor itself is less likely to thrive as the cells die off, Yang said.

"We have shown that only the BRCA2 is associated with better chemotherapy response, better progression
'/>"/>

Copyright©2010 ScoutNews,LLC.
All rights reserved  

Page: 1 2 3 4

Related medicine news :

1. Mutant gene identified that causes abnormal chromosome count, leading to cancer
2. Improved method for detecting mutant DNAs
3. How to make the best decisions when at high risk for breast or ovarian cancer
4. Foster Friess commits up to $50,000 to help TGen fight ovarian cancer
5. Study finds delay in referrals for older women with ovarian cancer
6. Pre-Diagnosis Diet Linked to Ovarian Cancer Survival
7. Only women with Western Swedish breast cancer gene run higher risk of ovarian cancer
8. Ovarian cancer study offers vital clues for new therapies
9. Researchers identify a new breast and ovarian cancer susceptibility gene
10. Study Makes Strides in Understanding Ovarian Cancer
11. PMH cancer researchers link ovarian hormone to breast stem cells growth
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Mutant Gene That Ups Risk for Ovarian Cancer May Aid Survival
(Date:7/22/2014)... (PRWEB) July 22, 2014 Garland’s new ... is designed to be used as a flood coat ... systems or as a premium restoration material. It provides ... the long-term performance and reducing life-cycle costs. Energizer BK ... to provide excellent water resistance in addition to superior ...
(Date:7/22/2014)... The hair transplant experts at WeGrowHair.com ... assisted laser therapy and robotic assisted hair transplantation ... women suffering from hair loss. Alongside their unique ... Unit Extraction (FUE) procedures via ARTAS – the ... technology, their doctors use advanced digital mapping to ...
(Date:7/21/2014)... sports in the United States, with more than 170,000 ... participation numbers, however, mean that more young people than ... and competition. , In a study published online today ... and available in an upcoming print issue, researchers from ... Children,s Hospital and the Colorado School of Public Health ...
(Date:7/21/2014)... July 21, 2014 As reported by ... Westin Hotel to Raise Addiction Awareness (7/15), thrill-seeking participants ... down a 27-story building in Downtown Philly. 100 people, ... event at the Westin Convention Center Hotel. Some of ... addiction. One man participated because his son killed himself ...
(Date:7/21/2014)... who have a clot in their legs and ... blood-thinning medication or undergo a minimally-invasive catheter-based clot ... no difference in death rates between the two ... the catheter procedure, according to a study by ... involved a review of more than 90,000 cases ...
Breaking Medicine News(10 mins):Health News:Energizer® BK Waterproof Coating from Garland Canada Reduces Life-Cycle Costs 2Health News:WeGrowHair.com/PAI Medical Group Introduces Robotic Assisted Laser Therapy to Treat Hair Loss 2Health News:New study finds high school lacrosse players at risk for concussions, other injuries 2Health News:New study finds high school lacrosse players at risk for concussions, other injuries 3Health News:100 People Climb Down Building to Raise Drug Addiction Awareness in Philadelphia 2Health News:100 People Climb Down Building to Raise Drug Addiction Awareness in Philadelphia 3Health News:Temple study compares deep vein thrombosis therapies 2Health News:Temple study compares deep vein thrombosis therapies 3Health News:Temple study compares deep vein thrombosis therapies 4
... international HIV and AIDS charity AVERT is today launching Stop ... to the 380,000 child AIDS deaths and half a ... ,At this year's G8 summit in Germany, the leaders ... to stop child AIDS deaths by committingspecific funds for prevention ...
... mental well being of young children of today seems to ... NCH, the childrens charity, found that one in ten ... significant level. ,The research says that More than a ... number in a generation. Emotional problems and conduct disorders have ...
... Washington University School of Medicine in St. Louis have ... by revealing that smoking interferes with ligament healing. ... model and found that cigarette smoking impairs the recruitment ... following ligament repair surgery. ,The researchers ...
... More than 60 people had to be treated in hospital ... a polluted Chinese river, state media reported Wednesday. ... their clothes in the Jindong River in eastern Anhui province ... few hours later, Xinhua news agency reported. ,The ...
... have found that a particular resonance pattern in the ... ability to discriminate speech. ,In the ... and Huan Luo report that the inherent rhythm of ... sentences by changing its phase. ,The researchers ...
... recalls how she lost her father, mother and father-in-law to ... to Panama from China. "It's very painful. The three had ... she says, her voice shaking with emotion. ,The ... found to be tainted. At least 80 people in Panama ...
Cached Medicine News:Health News:AIDS Charity AVERT Launches Stop AIDS in Children Campaign 2Health News:Mental Health of Children on the Decline 2Health News:Smoking Hampers Healing of the Ligament 2Health News:Dozens of Panamanians Gravely Ill from Toxic Substance from China 2
(Date:7/21/2014)...  Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR ) ... (FDA) accepted the company,s Investigational New Drug (IND) application ... efficacy of AVP-786, Avanir,s next generation compound. The company ... adjunctive treatment of major depressive disorder (MDD) during the ... endorsement of this Phase II study by the division ...
(Date:7/21/2014)... 21, 2014 Sorrento Therapeutics, Inc. (NASDAQ: ... developing new treatments for cancer and its associated pain, ... the preclinical development of a small molecule inhibitor targeting ... The Myc protein has also been recognized as an ... is involved as a dominant factor in most human ...
(Date:7/21/2014)... LA JOLLA, Calif. , July 21, 2014 ... RGLS ), a biopharmaceutical company leading the discovery ... today that the U.S. Food & Drug Administration ... a single stranded, chemically modified oligonucleotide that binds ... as a therapeutic for the treatment of Alport ...
Breaking Medicine Technology:Avanir Pharmaceuticals Announces FDA Acceptance of IND for AVP-786 for the Adjunctive Treatment of Major Depressive Disorder 2Avanir Pharmaceuticals Announces FDA Acceptance of IND for AVP-786 for the Adjunctive Treatment of Major Depressive Disorder 3Avanir Pharmaceuticals Announces FDA Acceptance of IND for AVP-786 for the Adjunctive Treatment of Major Depressive Disorder 4Avanir Pharmaceuticals Announces FDA Acceptance of IND for AVP-786 for the Adjunctive Treatment of Major Depressive Disorder 5Sorrento Awarded Grant from the National Institutes of Health for the Development of a Small Molecule Myc Inhibitor 2Sorrento Awarded Grant from the National Institutes of Health for the Development of a Small Molecule Myc Inhibitor 3Sorrento Awarded Grant from the National Institutes of Health for the Development of a Small Molecule Myc Inhibitor 4Regulus Receives Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport Syndrome 2Regulus Receives Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport Syndrome 3Regulus Receives Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport Syndrome 4Regulus Receives Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport Syndrome 5
... Inc. (OTCPK: SNDY) is pleased to announce that the Company ... in the amount of $90,005. The revenue for the three ... fifty Hospitals, Clinics, Healthcare Centers, Medical Centers and Surgery Centers ... growth in 2011 through new product development, new product sales ...
... Ireland, Jan. 27, 2011 Tibotec Pharmaceuticals today ... to generic manufacturers including Hetero Drugs Limited, Matrix ... Aspen Pharmacare of South Africa to manufacture, market ... rilpivirine hydrochloride (TMC278), pending ...
Cached Medicine Technology:Solos Endoscopy, Inc. Reports $90,005 in Sales Revenue for Fourth Quarter 2010 2Tibotec Signs Multiple Agreements With Generic Manufacturers to Provide Access to New HIV Treatment 2Tibotec Signs Multiple Agreements With Generic Manufacturers to Provide Access to New HIV Treatment 3Tibotec Signs Multiple Agreements With Generic Manufacturers to Provide Access to New HIV Treatment 4